Show results for
Refine by
Immune Deficiency Suppliers Serving Moldova
5 companies found
based inCham, SWITZERLAND
Agappe was established in 1995 with a vision “To be the Best Partner in the Diagnostic Field for the Welfare of Mankind”. This has guided us since our inception and helped us to consolidate our position as the fastest-growing In-Vitro Diagnostic ...
Mispa Count X Plus is a quantitative Auto Hematology Analyzer and 3-part differential counter for in Vitro Diagnostic Use in clinical laboratories. The purpose of this analyzer is to identify the normal patient, with all normal system-generated ...
based inSpringfield, NEW JERSEY (USA)
DRG International, Inc. is a leading manufacturer of clinical diagnostic and research ELISAs with distributors in over 110 countries. DRG is also the manufacturer of the DRG:HYBRiD-XL, a fully automated analyzer for Immunoassays and Clinical ...
based inKing of Prussia, PENNSYLVANIA (USA)
Behring's parent company, CSL, was formed more than 100 years ago to save lives using the latest technologies. In the century since, CSL Behring has grown into a global biotechnology leader, driven by that same promise to save and improve lives. We ...
based inDreieich, GERMANY
Biotest - innovation in haematology, clinical immunology and intensive care medicine. Biotest is a specialist in innovative haematology, clinical immunology and intensive care medicine. Biotest develops, manufactures and markets plasma proteins and ...
IgG Next Generation is a new development of a polyvalent immunglobulin (IVIG) for the treatment of immunedeficiencies and auto immune diseases. IgG Next Generation is being manufactured with a new and innovative production process and will be the ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Tasquinimod is an oral antiangiogenic agent, which has the potential for castration-resistant prostate cancer treatment. Tasquinimod binds to the regulatory Zn2+ binding domain of HDAC4 with Kd of 10-30 nM. Tasquinimod also is a S100A9 ...